AURORA CANNABIS INC 6-K Filing

From the Filing

0001279569-25-001175.txt : 20251105 0001279569-25-001175.hdr.sgml : 20251105 20251105072530 ACCESSION NUMBER: 0001279569-25-001175 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20251105 FILED AS OF DATE: 20251105 DATE AS OF CHANGE: 20251105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 251451771 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News release dated November 5, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: November 5, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED NOVEMBER 5, 2025 Exhibit 99.1 Aurora Cannabis Announces Fiscal 2026 Second Quarter Results • Expands YoY Global Medical Cannabis Net Revenue 1 by 15% to Record $70.5 million • Increases International Medical Cannabis Net Revenue 1 by 22% to Record $42.7 million, with leadership positions across key markets • Delivers Adjusted EBITDA 1 growth of 52%, reaching $15.4 million • Maintains Strong Balance Sheet with $141.9 million of Cash and Debt-Free Cannabis Business 2 NASDAQ | TSX: ACB EDMONTON, AB, Nov. 5, 2025 /CNW/ - Aurora Cannabis Inc. (the "Company" or "Aurora" ) (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2026 period ending September 30, 2025. "Aurora's quarterly performance highlights our continued focus on profitable growth. We achieved record net revenue 1 for global medical cannabis representing a 15% year-over-year increase, while adjusted EBITDA 1 rose 52%. These strong results affirm our strategic prioritization of medical cannabis as the industry's most compelling growth area," said Executive Chairman and Chief Executive Officer, Miguel Martin. "Our number one position in Canada, and our leadership positions in other key international medical cannabis markets, is the result of executing a disciplined strategy based upon world-class manufacturing and people, cutting-edge breeding and genetics, and regulatory expertise. The investments we have made in our facilities and people provide us with the capacity and consistency of supply to effectively compete in the rapidly expanding, high margin, market for medical cannabis," continued Mr. Martin. "Looking ahead, we intend to deliver continued strong results for our shareholders supported by a sizable cash balance and debt-free 2 cannabis business," concluded Mr. Martin. __________________________________ 1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP fina